Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Metrics to compare | EVLO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipEVLOPeersSector | |
---|---|---|---|---|
P/E Ratio | 0.0x | −4.7x | −0.5x | |
PEG Ratio | 0.00 | −0.01 | 0.00 | |
Price/Book | 0.0x | 2.1x | 2.6x | |
Price / LTM Sales | 0.0x | 9.6x | 3.2x | |
Upside (Analyst Target) | 0.0% | 178.3% | 40.5% | |
Fair Value Upside | Unlock | 6.7% | 4.4% | Unlock |